{"entity":{"id":"nct00045149","kind":"trial","name":"CD8+ T-cell clones against cancer-testis antigens in metastatic melanoma (Fred Hutchinson phase 1)","aka":[],"tldr":"A Seattle safety trial of killer T cells grown to recognise cancer-testis proteins, which melanomas can carry but most normal adult tissues do not. It ran from 2002 to 2005.","summary":"The registry describes a phase I safety study of autologous CD8+ antigen-specific T-cell clones targeting cancer-testis antigens in metastatic melanoma, started in October 2002 and completed in June 2005; no enrolment figure is given (ClinicalTrials.gov NCT00045149). Cassian Yee is listed as study chair, the sponsor is Fred Hutchinson Cancer Center with the National Cancer Institute as collaborator, and the interventions are aldesleukin and therapeutic T cells (ClinicalTrials.gov NCT00045149). No results are posted.","status":"completed","asOf":"2026-11-05","links":[{"label":"ClinicalTrials.gov NCT00045149","url":"https://clinicaltrials.gov/study/NCT00045149"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["aldesleukin"],"companies":[],"institutions":["fred-hutch","nci"],"pathways":[],"terms":["endogenous-t-cell-therapy"],"trials":[],"people":["cassian-yee"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo agent (Claude Opus 5.5)","editedOn":"2026-11-05","note":"Written from the MD Anderson faculty profile, ORCID, Europe PMC, ClinicalTrials.gov v2, SEC EDGAR and each organisation's own site, read on 5 November 2026."},"nct":"NCT00045149","phase":"1","setting":"Metastatic melanoma: autologous CD8+ antigen-specific T-cell clones targeting cancer-testis antigens, with aldesleukin","sponsor":"Fred Hutchinson Cancer Center, with the National Cancer Institute","result":"No results posted on ClinicalTrials.gov.","started":"2002-10","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct00045149/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"aldesleukin","kind":"drug","name":"Aldesleukin (high-dose IL-2)","route":"/drugs/aldesleukin/"}],"institution":[{"id":"fred-hutch","kind":"institution","name":"Fred Hutchinson Cancer Center","route":"/institutions/fred-hutch/"},{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/"}],"term":[{"id":"endogenous-t-cell-therapy","kind":"term","name":"Endogenous T-cell therapy","route":"/terms/endogenous-t-cell-therapy/"}],"person":[{"id":"cassian-yee","kind":"person","name":"Cassian Yee","route":"/people/cassian-yee/"}]}}